Smith & Nephew plc Given “Neutral” Rating at Goldman Sachs (SNN)
A number of other analysts have also recently weighed in on SNN. Analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Wednesday, June 11th. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Friday, June 6th. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Thursday, June 5th. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $97.00.
Shares of Smith & Nephew plc (NYSE:SNN) traded down 2.28% during mid-day trading on Tuesday, hitting $88.84. The stock had a trading volume of 322,668 shares. Smith & Nephew plc has a one year low of $55.22 and a one year high of $100.90. The stock has a 50-day moving average of $84.9 and a 200-day moving average of $77.26. The company has a market cap of $15.867 billion and a P/E ratio of 29.14. Smith & Nephew plc also saw a significant growth in short interest in the month of June. As of June 13th, there was short interest totalling 769,246 shares, a growth of 52.2% from the May 30th total of 505,437 shares. Based on an average daily trading volume, of 551,834 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.0% of the company’s shares are short sold.
Smith & Nephew plc (NYSE:SNN) last released its earnings data on Thursday, May 1st. The company reported $0.89 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.93 by $0.04. Analysts expect that Smith & Nephew plc will post $4.14 EPS for the current fiscal year.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.